Abstract:AimTo screen the genes of SLC4A gene family that can be used as candidate targets and prognostic markers in low-grade glioma (LGG) by bioinformatics analysis. MethodsThe differential expression, prognostic value, genetic changes and protein interaction of SLC4A in patients with low-grade gliomas were analyzed, by using TCGA, GTEx, UCSCXENA, GEPIA, cBioPortal, GeneMANIA, String. Based on the data, SLC4A family genes were screened as LGG candidate targets and prognostic markers. ResultsThe results indicated that the expression of SLC4A2, SLC4A4, SLC4A7 and SLC4A8 was increased in LGG tissue, whereas the expression of SLC4A1, SLC4A3, SLC4A9 and SLC4A10 was decreased. SLC4A2, SLC4A3, SLC4A4, SLC4A7 and SLC4A10 were significantly differently expressed with LGG tumor grades. Through the analysis of overall survival (OS) by prognostic value analysis, it was shown that patients with high expression of SLC4A2, SLC4A3, SLC4A7 and SLC4A8, and the low expression of SLC4A5 and SLC4A10, had poor prognosis. In the analysis of disease-free survival (DFS), patients with high expression of SLC4A2, SLC4A3 and SLC4A8, and low expression of SLC4A10, had poor prognosis. ConclusionSLC4A2, SLC4A3, SLC4A7, SLC4A8 and SLC4A10 could be Candidate Targets and Prognostic Biomarkers for LGG patients.